For histopathological analysis, haematoxylin and eosin and Verhoeff-Van Gieson stains were prepared from one block per lobe (thus, two blocks for single lung transplant (one each from the upper and lower lobes) and four blocks for double lung transplant (one from the upper and lower lobes of each lung). PVOD pattern was classified as absent (0), mild (1+) or moderate-severe (2+). Pulmonary veins and venules were examined for changes of PVOD: intimal thickening, obstructive fibrous luminal septa or recanalisation and arterialisation of pulmonary veins. Angioma-like lesions were reported in capillaries. Pulmonary arteries were evaluated for plexiform lesions, eccentric intimal fibrosis, concentric intimal fibrosis, recanalising thrombosis and muscularisation of small arteries. In addition to vascular pathology, the pulmonary interstitium was examined for usual interstitial pneumonia, nonspecific interstitial pneumonia, emphysema and pneumonitis. Comprehensive vessel morphometry was also performed on @ERSpublications There is an unexpectedly high incidence of PVOD in patients with SSc-PH-ILD. Presence of PVOD may be an unrecognised contributor to the dismal prognosis of these patients. Early transplant referral should be considered for those with SSc-PH-ILD. http://ow.ly/vPvc30neJZV five arterioles and venules per lobe of the lung. Measurements included external and lumen diameter, and smooth muscle and intimal thickness.
Institutional review board approval was obtained from University of Pittsburgh (Pittsburgh, PA, USA) for completion of the study.
The continuous variables were analysed with Kwallis and categorical variables with Fisher's exact test. A p-value <0.05 was considered statistically significant. All analyses were performed with STATA (StataCorp, College Station, TX, USA).
Of 24 SSc patients who received tranplants, 18 SSc patients met the inclusion criteria for the study and they all had SSc-PH-ILD. Of these, nine had 1+ PVOD and six had 2+ PVOD. There was no significant difference in demographics amongst the groups, though the odds of having one higher category of PVOD increased 10-fold in those with limited versus diffuse scleroderma (95% CI 0.77-133.4, p=0.07) ( figure 1 and table 1 ). Echocardiography was reviewed in all patients and there were no differences in right ventricular systolic pressure (table 1). Diffusing capacity was significantly lower in patients with PVOD (table 1). There was no significant difference in other pulmonary function test parameters, 6-min walk test distance and need for oxygen.
Patients with PVOD had lower pulmonary artery pressures compared to those with no PVOD (table 1) . There was no significant difference in cardiac output/index or pulmonary vascular resistance among the groups. One of the 1+ PVOD patient had pulmonary arterial wedge pressure 17 mmHg and pulmonary vascular resistance 1.5 Wood units. Compared to IPAH, no plexiform lesions were seen in SSc patients (table 1). The pulmonary vein smooth muscle percentage was lower in 2+ PVOD. See table 1 for details in differences in the pathology characteristics and morphometric analysis between different groups.
Our study suggests that there is a high incidence of PVOD in patients with SSc-PH-ILD. Also, the prevalence is higher in those with limited versus diffuse SSc. This finding of PVOD may be an unrecognised contributor to the dismal prognosis of these patients.
Interestingly, plexiform arteriopathy, a hallmark of IPAH, was not seen in any of the SSc-PH-ILD patients. Recent studies have reported an association of PVOD with SSc-PAH [11, 12] . OVERBEEK et al. [13] described eight patients with SSc-PAH, of whom four had changes consistent with PVOD. None of these had plexiform changes compared to 10 IPAH patients analysed who all had plexiform lesions. DORFMULLER et al. [14] studied eight patients with connective tissue disease-induced PAH, of whom four had limited SSc. Six of the eight patients had PVOD changes. Based on our literature search, all studies reported patients with SSc-PAH and there were no studies that specifically looked at SSc-PH-ILD.
SSc-PH-ILD has five-fold increased risk of death compared to SSc-PAH. LE PAVEC et al. [7] reported no clear benefit of PAH therapy in SSc-PH-ILD patients and extremely poor survival. The poor prognosis in this population has been attributed to worsening ventilation-perfusion mismatch. Our results suggest that a higher prevalence of PVOD may also play a role. Early transplant referral should be considered in these patients as they are refractory to pulmonary vasodilator therapy.
The higher than expected incidence of PVOD in SSc-PH-ILD patients could be due to selection bias in using explanted lungs, as these patients might have deteriorated faster than those without PVOD and may have been refractory to pulmonary vasodilator therapy, thus requiring lung transplantation. Eukaryotic translational initiation factor 2α kinase (EIF2AK4) gene and bone morphogenetic protein receptor type II (BMPR2) gene mutations have been reported with PVOD. We do not have information to investigate the genetic basis of this in our patient population. Further studies are needed.
In conclusion, our study is the first to highlight the high prevalence of PVOD in patients with SSc-PH-ILD, potentially contributing to the poor prognosis of this disease. 
